drugset / Trial / NCT04082910
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeric antigen receptor T (CAR T) cell infusions, its effects on the serum levels of Interleukin-6 (IL-6) and other cytokines.
Timeline
- Start
- 2019-09-15
- Primary completion
- 2022-12-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metoprolol | Other / unclassified | 12.5 mg | — |
| Subject | Metoprolol | Other / unclassified | 25 mg | — |
| Background | Etanercept | Protein / enzyme biologic | — | — |
| Background | Infliximab | Monoclonal antibody | — | — |
| Background | Tocilizumab | Monoclonal antibody | — | — |